Emily Lau (General Cardiology Fellow, Massachusetts General Hospital, Boston, MA, USA) speaks to us about the topic of her presentation ‘The Association of Cardiovascular Disease and Future Cancer’, presented at the American Heart Association (AHA) Scientific Sessions 2019.
Speaker’s Disclosures: Dr. Lau has nothing to declare in relation to this video interview.
1. Please tell us about your research, the motivations behind it and some of the findings? (0:11)
2. Do you think that physicians will be able to take this research and apply it to day-to-day practice right away? (2:19)
3. What future research do you think still needs to be done? (3:19)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Cardiovascular Disease
Michael Reardon, ACC 2022: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael Reardon (Houston Methodist Hospital, Houston, TX) shares the insights and findings from these trials. Questions: […]
Milind Desai, ACC 2022: VALOR-HCM Trial
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future […]
Milind Desai, ACC 2022: VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
An overview about the risks of surgical septal myectomy and alcohol ablation as treatments for obstructive hypertrophic cardiomyopathy and how mavacamten can provide an alternative was given by Prof. Milind Desai (Cleveland Clinic, Cleveland, OH). The presentation entitled ‘VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!